Ottimo Pharma
ottimopharma.com
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$140M
5 rounds on record
Latest round
Venture round
Feb 2025 · 20 mo ago
Team
201-500
employees, estimated range
Backers
1
OrbiMed
The money's age
Due for its next round
20 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 7
Certified Ottimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-… · ottimopharma.com
Apr 10, 2025
Board appointment Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors · ottimopharma.com
Feb 20, 2025
Raised a round Venture round
Dec 19, 2024
Raised a round Series A $140M
Oct 28, 2024
Launched Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2… · ottimopharma.com
Apr 12, 2021
Raised a round Venture round
Oct 6, 2020
Raised a round Venture round
Apr 6, 2017
Raised a round Venture round
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Feb 2025 | — | — | find-and-update.company-information.service.gov.uk |
| Series A | Dec 2024 | $140M | — | ottimopharma.com |
| Venture round | Apr 2021 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Oct 2020 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Apr 2017 | — | — | find-and-update.company-information.service.gov.uk |
Registers and programsofficial lists and records that name the company
| Legal entity | Ottimo Pharma Limited | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
OrbiMed Investors in similar startupsfunds that back the companies most like this one
backs Windward Bio
Similar startupsby what they do, their industry and backers
Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation adjuvanted subunit vaccines to the market…
Createrna is an innovative drug research and development company in the clinical stage.
Our Mission. Deliver medicines that transform the lives of patients with neurodegenerative diseases.
Anodyne Nanotech is a clinical-stage biotech company, developing transdermal premium products for the treatment of chronic diseases.
THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse…
Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological…
News
Ottimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-PD-1/VEGFR2 Antibody
First patient dosed and study open in leading oncology centers in US and Australia Phase I/IIA adaptive study aims to assess and optimize the dose of OTP-01 and provide safety, tolerability, and early efficacy data initially in patients known to benefit f
Read more
Report
Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors
Ottimo Pharma ("Ottimo"), an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual paratopic antibodies to extend the lives of patients living with cancer, today announces the appointment of Roger Dansey, M.D., a prominent leader in oncolog
Read more
Report
Ottimo Pharma Strengthens Leadership Team with Senior Appointments
Ottimo Pharma ("Ottimo"), an innovative biotech company developing one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of patients living with cancer, today announces the appointment of Robert Tighe as Senior Vice President of Preclinical
Read more
Report
Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 2025
Ottimo Pharma, a private biotech company, announces the appointment of world class industry veterans David Epstein as Chair & Chief Executive Officer, Mehdi Shahidi as Head of Development & Chief Medical Officer and James Sabry as Vice-Chair of the Board
Read more
Report
Financials
Total raised
$140M
Latest round
Venture - Series Unknown
Funding rounds
5